Brokerages expect that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will report sales of $50,000.00 for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals reported sales of $380,000.00 in the same quarter last year, which would suggest a negative year-over-year growth rate of 86.8%. The firm is expected to announce its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $140,000.00 for the current year, with estimates ranging from $110,000.00 to $200,000.00. For the next fiscal year, analysts expect that the company will report sales of $140,000.00, with estimates ranging from $100,000.00 to $200,000.00. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%.

AUPH has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 10th. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 3rd. Citigroup initiated coverage on shares of Aurinia Pharmaceuticals in a research report on Monday, September 9th. They issued an “outperform” rating and a $14.00 price objective on the stock. Bloom Burton reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $15.18.

Aurinia Pharmaceuticals stock opened at $4.88 on Tuesday. Aurinia Pharmaceuticals has a 52-week low of $3.52 and a 52-week high of $7.85. The company’s 50 day moving average is $5.43 and its two-hundred day moving average is $6.06. The firm has a market cap of $451.63 million, a PE ratio of -6.42 and a beta of 1.11.

Several large investors have recently made changes to their positions in the business. Orbimed Advisors LLC increased its position in shares of Aurinia Pharmaceuticals by 12.1% in the 2nd quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock valued at $23,234,000 after purchasing an additional 381,192 shares during the last quarter. Vivo Capital LLC increased its position in shares of Aurinia Pharmaceuticals by 57.7% in the 2nd quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock valued at $12,592,000 after purchasing an additional 700,333 shares during the last quarter. BlackRock Inc. increased its position in shares of Aurinia Pharmaceuticals by 3.1% in the 2nd quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock valued at $6,063,000 after purchasing an additional 28,129 shares during the last quarter. Swiss National Bank grew its position in shares of Aurinia Pharmaceuticals by 14.0% in the 2nd quarter. Swiss National Bank now owns 111,800 shares of the biotechnology company’s stock valued at $738,000 after buying an additional 13,700 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Aurinia Pharmaceuticals by 35.5% in the 2nd quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 20,432 shares during the last quarter. 31.12% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: Should I follow buy, hold and sell recommendations?

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.